GMDAQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GMDAQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gamida Cell has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Gamida Cell did not have earnings to cover the interest expense. Gamida Cell's debt to revenue ratio for the quarter that ended in Dec. 2023 was 18.66. As of today, Gamida Cell's Altman Z-Score is -7.47.
For the Biotechnology subindustry, Gamida Cell's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Gamida Cell's Financial Strength distribution charts can be found below:
* The bar in red indicates where Gamida Cell's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Gamida Cell's Interest Expense for the months ended in Dec. 2023 was $-9.54 Mil. Its Operating Income for the months ended in Dec. 2023 was $-16.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $75.17 Mil.
Gamida Cell's Interest Coverage for the quarter that ended in Dec. 2023 is
Gamida Cell did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Gamida Cell's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Dec. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (7.775 | + | 75.168) | / | 4.444 | |
= | 18.66 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Gamida Cell has a Z-score of -7.47, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -7.47 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gamida Cell (OTCPK:GMDAQ) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Gamida Cell has the Financial Strength Rank of 0.
Thank you for viewing the detailed overview of Gamida Cell's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeremy Blank | director | 6446 DREXEL AVENUE, LOS ANGELES CA 90048 |
Mary Theresa Coelho | officer: Chief Financial Officer | 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
Ronit Simantov | officer: CMO & Chief Scientific Officer | 1988 CHAPEL STREET, NEW HAVEN CT 06515 |
Abigail L. Jenkins | director, officer: President and CEO | C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116 |
Stephen T Wills | director | PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Ivan M. Borrello | director | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
Anat Cohen-dayag | director | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
Naama Halevi-davidov | director | C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003 |
Joshua F. Patterson | officer: General Counsel | C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210 |
Bio Medical Investment (1997) Ltd. | other: Affiliate of 10% Owner | 3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301 |
Shai Lankry | officer: Chief Financial Officer | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
Ai Gamida Holdings Llc | other: Affiliate of 10% Owner | 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Ofer Gonen | director | 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102 |
Clal Biotechnology Industries Ltd. | other: Affiliate of 10% Owner | 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023 |
Len Blavatnik | 10 percent owner | C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019 |
From GuruFocus
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.